Best products for redness & sensitivity

Mechanistic review: niacinamide inhibits melanosome transfer via PAR-2 downregulation, upregulates ceramide and fatty acid synthesis for barrier repair, and reduces TEWL; Korean government-funded with no industry conflicts; notes most clinical trials are industry-sponsored

Niacinamide 4% comparable to hydroquinone 4% for melasma treatment (MASI reduction 43% vs 55%, p=ns); niacinamide showed significantly fewer side effects (0% vs 18% irritation); independently funded with no industry involvement

Randomized controlled trial: Independent replication of melanosome transfer mechanism and reversibility.

Randomized controlled trial (8 weeks): Acne efficacy vs topical antibiotic.

5% niacinamide significantly reduced skin yellowing (sallowness), wrinkling, and red blotchiness versus vehicle at 12 weeks by both instrumental and clinical assessment; P&G-funded with all authors affiliated with Procter & Gamble

Dose-finding study (n=79): 5% niacinamide significantly reduced hyperpigmentation and inhibited melanosome transfer versus vehicle (p<0.05); 2% concentration did not reach statistical significance for any endpoint; establishes 5% as minimum effective dose for pigmentation

Split-face RCT (n=50): 5% niacinamide moisturizer significantly reduced hyperpigmented spots, wrinkles, red blotchiness, and skin sallowness versus vehicle at 12 weeks; Procter & Gamble-funded — authors are P&G employees with financial interest in the formulation tested

Randomized controlled trial (n=50, 12 weeks): Replication and elasticity endpoint addition.

Clinical study: Niacinamide plus N acetylglucosamine synergy for hyperpigmentation.

Niacinamide dose-dependently stimulated ceramide synthesis (2.2-fold at 10 mM), free fatty acid synthesis, and cholesterol synthesis in cultured keratinocytes; proposed mechanism for barrier-repair activity observed in clinical trials

Mechanistic review: niacinamide inhibits melanosome transfer via PAR-2 downregulation, upregulates ceramide and fatty acid synthesis for barrier repair, and reduces TEWL; Korean government-funded with no industry conflicts; notes most clinical trials are industry-sponsored

Niacinamide 4% comparable to hydroquinone 4% for melasma treatment (MASI reduction 43% vs 55%, p=ns); niacinamide showed significantly fewer side effects (0% vs 18% irritation); independently funded with no industry involvement

Randomized controlled trial: Independent replication of melanosome transfer mechanism and reversibility.

Randomized controlled trial (8 weeks): Acne efficacy vs topical antibiotic.

5% niacinamide significantly reduced skin yellowing (sallowness), wrinkling, and red blotchiness versus vehicle at 12 weeks by both instrumental and clinical assessment; P&G-funded with all authors affiliated with Procter & Gamble

Dose-finding study (n=79): 5% niacinamide significantly reduced hyperpigmentation and inhibited melanosome transfer versus vehicle (p<0.05); 2% concentration did not reach statistical significance for any endpoint; establishes 5% as minimum effective dose for pigmentation

Split-face RCT (n=50): 5% niacinamide moisturizer significantly reduced hyperpigmented spots, wrinkles, red blotchiness, and skin sallowness versus vehicle at 12 weeks; Procter & Gamble-funded — authors are P&G employees with financial interest in the formulation tested

Randomized controlled trial (n=50, 12 weeks): Replication and elasticity endpoint addition.

Clinical study: Niacinamide plus N acetylglucosamine synergy for hyperpigmentation.

Niacinamide dose-dependently stimulated ceramide synthesis (2.2-fold at 10 mM), free fatty acid synthesis, and cholesterol synthesis in cultured keratinocytes; proposed mechanism for barrier-repair activity observed in clinical trials

Mechanistic review: niacinamide inhibits melanosome transfer via PAR-2 downregulation, upregulates ceramide and fatty acid synthesis for barrier repair, and reduces TEWL; Korean government-funded with no industry conflicts; notes most clinical trials are industry-sponsored

Niacinamide 4% comparable to hydroquinone 4% for melasma treatment (MASI reduction 43% vs 55%, p=ns); niacinamide showed significantly fewer side effects (0% vs 18% irritation); independently funded with no industry involvement

Randomized controlled trial: Independent replication of melanosome transfer mechanism and reversibility.

Randomized controlled trial (8 weeks): Acne efficacy vs topical antibiotic.

5% niacinamide significantly reduced skin yellowing (sallowness), wrinkling, and red blotchiness versus vehicle at 12 weeks by both instrumental and clinical assessment; P&G-funded with all authors affiliated with Procter & Gamble

Dose-finding study (n=79): 5% niacinamide significantly reduced hyperpigmentation and inhibited melanosome transfer versus vehicle (p<0.05); 2% concentration did not reach statistical significance for any endpoint; establishes 5% as minimum effective dose for pigmentation

Split-face RCT (n=50): 5% niacinamide moisturizer significantly reduced hyperpigmented spots, wrinkles, red blotchiness, and skin sallowness versus vehicle at 12 weeks; Procter & Gamble-funded — authors are P&G employees with financial interest in the formulation tested

Randomized controlled trial (n=50, 12 weeks): Replication and elasticity endpoint addition.

Clinical study: Niacinamide plus N acetylglucosamine synergy for hyperpigmentation.

Niacinamide dose-dependently stimulated ceramide synthesis (2.2-fold at 10 mM), free fatty acid synthesis, and cholesterol synthesis in cultured keratinocytes; proposed mechanism for barrier-repair activity observed in clinical trials

Mechanistic review: niacinamide inhibits melanosome transfer via PAR-2 downregulation, upregulates ceramide and fatty acid synthesis for barrier repair, and reduces TEWL; Korean government-funded with no industry conflicts; notes most clinical trials are industry-sponsored

Niacinamide 4% comparable to hydroquinone 4% for melasma treatment (MASI reduction 43% vs 55%, p=ns); niacinamide showed significantly fewer side effects (0% vs 18% irritation); independently funded with no industry involvement

Randomized controlled trial: Independent replication of melanosome transfer mechanism and reversibility.

Randomized controlled trial (8 weeks): Acne efficacy vs topical antibiotic.

5% niacinamide significantly reduced skin yellowing (sallowness), wrinkling, and red blotchiness versus vehicle at 12 weeks by both instrumental and clinical assessment; P&G-funded with all authors affiliated with Procter & Gamble

Dose-finding study (n=79): 5% niacinamide significantly reduced hyperpigmentation and inhibited melanosome transfer versus vehicle (p<0.05); 2% concentration did not reach statistical significance for any endpoint; establishes 5% as minimum effective dose for pigmentation

Split-face RCT (n=50): 5% niacinamide moisturizer significantly reduced hyperpigmented spots, wrinkles, red blotchiness, and skin sallowness versus vehicle at 12 weeks; Procter & Gamble-funded — authors are P&G employees with financial interest in the formulation tested

Randomized controlled trial (n=50, 12 weeks): Replication and elasticity endpoint addition.

Clinical study: Niacinamide plus N acetylglucosamine synergy for hyperpigmentation.

Niacinamide dose-dependently stimulated ceramide synthesis (2.2-fold at 10 mM), free fatty acid synthesis, and cholesterol synthesis in cultured keratinocytes; proposed mechanism for barrier-repair activity observed in clinical trials

Mechanistic review: niacinamide inhibits melanosome transfer via PAR-2 downregulation, upregulates ceramide and fatty acid synthesis for barrier repair, and reduces TEWL; Korean government-funded with no industry conflicts; notes most clinical trials are industry-sponsored

Niacinamide 4% comparable to hydroquinone 4% for melasma treatment (MASI reduction 43% vs 55%, p=ns); niacinamide showed significantly fewer side effects (0% vs 18% irritation); independently funded with no industry involvement

Randomized controlled trial: Independent replication of melanosome transfer mechanism and reversibility.

Randomized controlled trial (8 weeks): Acne efficacy vs topical antibiotic.

5% niacinamide significantly reduced skin yellowing (sallowness), wrinkling, and red blotchiness versus vehicle at 12 weeks by both instrumental and clinical assessment; P&G-funded with all authors affiliated with Procter & Gamble

Dose-finding study (n=79): 5% niacinamide significantly reduced hyperpigmentation and inhibited melanosome transfer versus vehicle (p<0.05); 2% concentration did not reach statistical significance for any endpoint; establishes 5% as minimum effective dose for pigmentation

Split-face RCT (n=50): 5% niacinamide moisturizer significantly reduced hyperpigmented spots, wrinkles, red blotchiness, and skin sallowness versus vehicle at 12 weeks; Procter & Gamble-funded — authors are P&G employees with financial interest in the formulation tested

Randomized controlled trial (n=50, 12 weeks): Replication and elasticity endpoint addition.

Clinical study: Niacinamide plus N acetylglucosamine synergy for hyperpigmentation.

Niacinamide dose-dependently stimulated ceramide synthesis (2.2-fold at 10 mM), free fatty acid synthesis, and cholesterol synthesis in cultured keratinocytes; proposed mechanism for barrier-repair activity observed in clinical trials

Mechanistic review: niacinamide inhibits melanosome transfer via PAR-2 downregulation, upregulates ceramide and fatty acid synthesis for barrier repair, and reduces TEWL; Korean government-funded with no industry conflicts; notes most clinical trials are industry-sponsored

Niacinamide 4% comparable to hydroquinone 4% for melasma treatment (MASI reduction 43% vs 55%, p=ns); niacinamide showed significantly fewer side effects (0% vs 18% irritation); independently funded with no industry involvement

Randomized controlled trial: Independent replication of melanosome transfer mechanism and reversibility.

Randomized controlled trial (8 weeks): Acne efficacy vs topical antibiotic.

5% niacinamide significantly reduced skin yellowing (sallowness), wrinkling, and red blotchiness versus vehicle at 12 weeks by both instrumental and clinical assessment; P&G-funded with all authors affiliated with Procter & Gamble

Dose-finding study (n=79): 5% niacinamide significantly reduced hyperpigmentation and inhibited melanosome transfer versus vehicle (p<0.05); 2% concentration did not reach statistical significance for any endpoint; establishes 5% as minimum effective dose for pigmentation

Split-face RCT (n=50): 5% niacinamide moisturizer significantly reduced hyperpigmented spots, wrinkles, red blotchiness, and skin sallowness versus vehicle at 12 weeks; Procter & Gamble-funded — authors are P&G employees with financial interest in the formulation tested

Randomized controlled trial (n=50, 12 weeks): Replication and elasticity endpoint addition.

Clinical study: Niacinamide plus N acetylglucosamine synergy for hyperpigmentation.

Niacinamide dose-dependently stimulated ceramide synthesis (2.2-fold at 10 mM), free fatty acid synthesis, and cholesterol synthesis in cultured keratinocytes; proposed mechanism for barrier-repair activity observed in clinical trials

Mechanistic review: niacinamide inhibits melanosome transfer via PAR-2 downregulation, upregulates ceramide and fatty acid synthesis for barrier repair, and reduces TEWL; Korean government-funded with no industry conflicts; notes most clinical trials are industry-sponsored

Niacinamide 4% comparable to hydroquinone 4% for melasma treatment (MASI reduction 43% vs 55%, p=ns); niacinamide showed significantly fewer side effects (0% vs 18% irritation); independently funded with no industry involvement

Randomized controlled trial: Independent replication of melanosome transfer mechanism and reversibility.

Randomized controlled trial (8 weeks): Acne efficacy vs topical antibiotic.

5% niacinamide significantly reduced skin yellowing (sallowness), wrinkling, and red blotchiness versus vehicle at 12 weeks by both instrumental and clinical assessment; P&G-funded with all authors affiliated with Procter & Gamble

Dose-finding study (n=79): 5% niacinamide significantly reduced hyperpigmentation and inhibited melanosome transfer versus vehicle (p<0.05); 2% concentration did not reach statistical significance for any endpoint; establishes 5% as minimum effective dose for pigmentation

Split-face RCT (n=50): 5% niacinamide moisturizer significantly reduced hyperpigmented spots, wrinkles, red blotchiness, and skin sallowness versus vehicle at 12 weeks; Procter & Gamble-funded — authors are P&G employees with financial interest in the formulation tested

Randomized controlled trial (n=50, 12 weeks): Replication and elasticity endpoint addition.

Clinical study: Niacinamide plus N acetylglucosamine synergy for hyperpigmentation.

Niacinamide dose-dependently stimulated ceramide synthesis (2.2-fold at 10 mM), free fatty acid synthesis, and cholesterol synthesis in cultured keratinocytes; proposed mechanism for barrier-repair activity observed in clinical trials

Mechanistic review: niacinamide inhibits melanosome transfer via PAR-2 downregulation, upregulates ceramide and fatty acid synthesis for barrier repair, and reduces TEWL; Korean government-funded with no industry conflicts; notes most clinical trials are industry-sponsored

Niacinamide 4% comparable to hydroquinone 4% for melasma treatment (MASI reduction 43% vs 55%, p=ns); niacinamide showed significantly fewer side effects (0% vs 18% irritation); independently funded with no industry involvement

Randomized controlled trial: Independent replication of melanosome transfer mechanism and reversibility.

Randomized controlled trial (8 weeks): Acne efficacy vs topical antibiotic.

5% niacinamide significantly reduced skin yellowing (sallowness), wrinkling, and red blotchiness versus vehicle at 12 weeks by both instrumental and clinical assessment; P&G-funded with all authors affiliated with Procter & Gamble

Dose-finding study (n=79): 5% niacinamide significantly reduced hyperpigmentation and inhibited melanosome transfer versus vehicle (p<0.05); 2% concentration did not reach statistical significance for any endpoint; establishes 5% as minimum effective dose for pigmentation

Split-face RCT (n=50): 5% niacinamide moisturizer significantly reduced hyperpigmented spots, wrinkles, red blotchiness, and skin sallowness versus vehicle at 12 weeks; Procter & Gamble-funded — authors are P&G employees with financial interest in the formulation tested

Randomized controlled trial (n=50, 12 weeks): Replication and elasticity endpoint addition.

Clinical study: Niacinamide plus N acetylglucosamine synergy for hyperpigmentation.

Niacinamide dose-dependently stimulated ceramide synthesis (2.2-fold at 10 mM), free fatty acid synthesis, and cholesterol synthesis in cultured keratinocytes; proposed mechanism for barrier-repair activity observed in clinical trials

Mechanistic review: niacinamide inhibits melanosome transfer via PAR-2 downregulation, upregulates ceramide and fatty acid synthesis for barrier repair, and reduces TEWL; Korean government-funded with no industry conflicts; notes most clinical trials are industry-sponsored

Niacinamide 4% comparable to hydroquinone 4% for melasma treatment (MASI reduction 43% vs 55%, p=ns); niacinamide showed significantly fewer side effects (0% vs 18% irritation); independently funded with no industry involvement

Randomized controlled trial: Independent replication of melanosome transfer mechanism and reversibility.

Randomized controlled trial (8 weeks): Acne efficacy vs topical antibiotic.

5% niacinamide significantly reduced skin yellowing (sallowness), wrinkling, and red blotchiness versus vehicle at 12 weeks by both instrumental and clinical assessment; P&G-funded with all authors affiliated with Procter & Gamble

Dose-finding study (n=79): 5% niacinamide significantly reduced hyperpigmentation and inhibited melanosome transfer versus vehicle (p<0.05); 2% concentration did not reach statistical significance for any endpoint; establishes 5% as minimum effective dose for pigmentation

Split-face RCT (n=50): 5% niacinamide moisturizer significantly reduced hyperpigmented spots, wrinkles, red blotchiness, and skin sallowness versus vehicle at 12 weeks; Procter & Gamble-funded — authors are P&G employees with financial interest in the formulation tested

Randomized controlled trial (n=50, 12 weeks): Replication and elasticity endpoint addition.

Clinical study: Niacinamide plus N acetylglucosamine synergy for hyperpigmentation.

Niacinamide dose-dependently stimulated ceramide synthesis (2.2-fold at 10 mM), free fatty acid synthesis, and cholesterol synthesis in cultured keratinocytes; proposed mechanism for barrier-repair activity observed in clinical trials

Mechanistic review: niacinamide inhibits melanosome transfer via PAR-2 downregulation, upregulates ceramide and fatty acid synthesis for barrier repair, and reduces TEWL; Korean government-funded with no industry conflicts; notes most clinical trials are industry-sponsored

Niacinamide 4% comparable to hydroquinone 4% for melasma treatment (MASI reduction 43% vs 55%, p=ns); niacinamide showed significantly fewer side effects (0% vs 18% irritation); independently funded with no industry involvement

Randomized controlled trial: Independent replication of melanosome transfer mechanism and reversibility.

Randomized controlled trial (8 weeks): Acne efficacy vs topical antibiotic.

5% niacinamide significantly reduced skin yellowing (sallowness), wrinkling, and red blotchiness versus vehicle at 12 weeks by both instrumental and clinical assessment; P&G-funded with all authors affiliated with Procter & Gamble

Dose-finding study (n=79): 5% niacinamide significantly reduced hyperpigmentation and inhibited melanosome transfer versus vehicle (p<0.05); 2% concentration did not reach statistical significance for any endpoint; establishes 5% as minimum effective dose for pigmentation

Split-face RCT (n=50): 5% niacinamide moisturizer significantly reduced hyperpigmented spots, wrinkles, red blotchiness, and skin sallowness versus vehicle at 12 weeks; Procter & Gamble-funded — authors are P&G employees with financial interest in the formulation tested

Randomized controlled trial (n=50, 12 weeks): Replication and elasticity endpoint addition.

Clinical study: Niacinamide plus N acetylglucosamine synergy for hyperpigmentation.

Niacinamide dose-dependently stimulated ceramide synthesis (2.2-fold at 10 mM), free fatty acid synthesis, and cholesterol synthesis in cultured keratinocytes; proposed mechanism for barrier-repair activity observed in clinical trials